TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2169784
Drug: Granisetron (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (40 micrograms/kg; n = 114) administered as a 5 min infusion, with two additional 40 micrograms/kg doses allowed
Study: 2169784
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide plus dexamethasone (120 patients) - Dexamethasone 12 mg intravenously over 30 min, followed by a loading dose of 3 mg/kg metoclopramide, then maintenance dose of 4 mg/kg over 8 h
Study: 31983056
Drug: SDZ-ADL (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDZ-ADL (40 mg)
Study: 31983056
Drug: Secukinumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (300 or 150 mg)
Study: 23496302
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections + self monitoring of blood glucose
Study: 21322181
Drug: sirdalud MR
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sirdalud MR (tizanidine modified release) 6 mg per day
Study: 21322181
Drug: sirdalud (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: sirdalud (standard form of tizanidine) 2 mg 3 times daily
Study: 7084076
Drug: Sequential compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential compression prophylaxis with 90-100 mm Hg
Study: 7084076
Drug: Sequential compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential compression with 35 mm Hg
Study: 7084076
Drug: Heparin 5000
Normalized name: HEPARIN 5000 UNT/ML SYRINGE 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 5000 units three times daily
Study: 31829173
Drug: Guanxinshutong (GXST)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanxinshutong (GXST) capsules
Study: 24856940
Drug: Circuit class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circuit class therapy sessions
Study: 28229515
Drug: Individual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapy sessions
Study: 15250431
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment modalities
Study: 11936567
Drug: Didanosine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (400 mg) with light meal
Study: 11936567
Drug: Didanosine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (400 mg) with yogurt
Study: 11936567
Drug: Didanosine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (400 mg) 2 hours after light meal
Study: 11936567
Drug: Didanosine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (400 mg) 1.5 hours before meal
Study: 28497478
Drug: Paroxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (30 mg)
Study: 27478346
Drug: Pulsed Radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Radiofrequency (PRF) administered to a targeted dorsal root ganglion (DRG)
Study: 15043665
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block with 0.25% bupivacaine 2 mg/kg
Study: 8350339
Drug: Diclofenac (Voltaren)
Normalized name: diclofenac Topical Gel [Voltaren]
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac (Voltaren) 50 mg per os 3 times a day (po tid)
Study: 23188186
Drug: Conventional Intensity‐Modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Intensity‐Modulated Radiation Therapy (IMRT)
Study: 10770814
Drug: Symptomatic antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic antibiotic treatment (3 treatments per year)
Study: 14530901
Drug: Memantine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (30 mg)
Study: 3721670
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide cream (0.1%) applied daily for 14 days under occlusion.
Study: 30450865
Drug: 7.2% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.2% saline solution + oral electrolyte solutions (OES)
Study: 30450865
Drug: Acetate Ringer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetate Ringer solution
Study: 30450865
Drug: Lactate Ringer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate Ringer solution
Study: 20862456
Drug: No patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: No patch (non-smokers)
Study: 10673888
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg orally once daily for 4 days
Study: 28245873
Drug: Atorvastatin 5
Normalized name: amlodipine-atorvastatin 5 mg-80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 5 mg/ezetimibe 10 mg combination
Study: 25567031
Drug: Brief strategic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief strategic therapy (BST) in conjunction with usual care (UC)
Study: 21293900
Drug: Eradication PPI-triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication PPI-triple therapy
Study: 21293900
Drug: Eradication PPI-triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication PPI-triple therapy (non-compliant patients)
Study: 7838921
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg caffeine
Study: 17925021
Drug: 3.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg/kg caffeine
Study: 7759706
Drug: Streptokinase/subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase/subcutaneous heparin
Study: 7759706
Drug: Streptokinase/intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase/intravenous heparin
Study: 110504
Drug: Thyrotrophin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotrophin-releasing hormone (TRH) 200 microgram/h
Study: 110504
Drug: Thyrotrophin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotrophin-releasing hormone (TRH) 40 microgram/h
Study: 110504
Drug: Thyrotrophin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotrophin-releasing hormone (TRH) 8 microgram/h
Study: 31807943
Drug: Intensive multimodal
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive multimodal treatment (TG)
Study: 25622197
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy for insomnia (CBTI-BP)
Study: 21108620
Drug: 0.3% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% ropivacaine combined with 1 μg/ml sufentanil (RS group, n=20)
Study: 19476115
Drug: Interval exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval exercise training (IET) - 15 min interval exercise sessions, 2 times daily for 3 weeks
Study: 23539696
Drug: Semuloparin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semuloparin (20 mg subcutaneously once daily)
Study: 20861846
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg on demand 1 hour before sexual activity
Study: 8629878
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (low-dose warfarin [INR <1.5] plus 325 mg/d of enteric-coated aspirin)
Study: 8629878
Drug: Adjusted-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose warfarin therapy (INR 2.0 to 3.0)
Study: 8629878
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (325 mg/d of enteric-coated aspirin)
Study: 8751522
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin
Study: 6143709
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sulphasalazine and levamisole
Study: 30885078
Drug: Warning against
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warning against driving after taking the medication
Study: 15041399
Drug: MMF 1000
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 1000 mg b.i.d.
Study: 22554491
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy in polygenic hypercholesterolemia (PH)
Study: 22554491
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy in familial combined hyperlipemia (FCH)
Study: 20597268
Drug: Warfarin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin alone (Group 1)
Study: 20597268
Drug: Warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plus aspirin (Group 2)
Study: 20597268
Drug: Warfarin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (both groups)
Study: 2413761
Drug: Adjunct use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct use of intraperitoneal dextran or hydrocortisone
Study: 29316012
Drug: Escalated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated therapy
Study: 9696215
Drug: Bromocriptine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine treatment
Study: 1481585
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine agonist trial
Study: 19463377
Drug: Clopidogrel 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 150 mg/day
Study: 19463377
Drug: Clopidogrel 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 150 mg/day after switching from 75 mg/day
Study: 14984519
Drug: Indomethacin (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (bolus of 0.2 mg.kg‐1 followed by an infusion of 0.2 mg.kg‐1.h‐1)
Study: 8482443
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day mesalamine
Study: 8482443
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day mesalamine (in patients with ileum-only disease)
Study: 3156614
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg kg‐1 i.m.
Study: 3156614
Drug: Diazepam 0.2
Normalized name: diazepam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.2 mg kg‐1 i.m.
Study: 30852971
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus Clopidogrel (A+C) therapy (short-term, ≤1 month)
Study: 30852971
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus Clopidogrel (A+C) therapy (intermediate-term, ≤3 months)
Study: 30852971
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus Clopidogrel (A+C) therapy (long-term, >3 months)
Study: 19674876
Drug: Investigational antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational antihypertensive drug
Study: 10029616
Drug: Nitroglycerin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (0.3 or 0.5 microgram.kg‐1.min‐1 intravenous)
Study: 468444
Drug: 2.8% THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.8% THC inhalation
Study: 25091346
Drug: Maltodextrin 2.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin 2.8 g twice daily for 8 weeks
Study: 17446567
Drug: CWS and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CWS and substance abuse treatment systems
Study: 12044508
Drug: Gemcitabine-radiotherapy (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine-radiotherapy (gemcitabine at 300 mg/m² concurrent with radiotherapy, three fractions of 8 Gy on days 1, 8, and 15; followed by gemcitabine alone at 1000 mg/m² weekly for 3 weeks every 4 weeks if compliance allowed)
Study: 9527088
Drug: Alcohol, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol, 1 g/kg body weight, mixed with 500 ml of juice
Study: 9527088
Drug: Alcohol, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol, 1 g/kg body weight, mixed with 500 ml of juice plus 750 ml of mineral water
Study: 881098
Drug: Slow aspirin
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow aspirin
Study: 28093483
Drug: Atazanavir/ritonavir +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir + lamivudine (300 mg atazanavir/100 mg ritonavir once daily and 300 mg lamivudine once daily)
Study: 19258984
Drug: Ultrasound-guided perivascular
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided perivascular sural nerve block (group US) with 5 mL of 3% chloroprocaine
Study: 19258984
Drug: Traditional landmark-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional landmark-based sural nerve block (group TRAD) with 5 mL of 3% chloroprocaine
Study: 14722635
Drug: Protective tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective tidal volumes (6 ml/kg, respiratory rate: 15 breaths/min, PEEP 5 cmH(2)O, n=15)
Study: 14722635
Drug: Conventional tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tidal volumes with PEEP (10 ml/kg, respiratory rate: 9 breaths/min, PEEP 5 cmH(2)O, n=14)
Study: 14722635
Drug: Conventional tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tidal volumes without PEEP (10 ml/kg, respiratory rate: 9 breaths/min, n=15)
Study: 7579511
Drug: Positive immunostaining
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive immunostaining for heat-shock protein-27 (HSP-27) using a polyclonal antibody (Hu27, dilution: 1/200)
Study: 2158487
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (intralesional stibogluconate injection and superficial cryotherapy)
Study: 2158487
Drug: Intralesional stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional stibogluconate injection alone
Study: 25817183
Drug: Topical 3g
Normalized name: Topicale
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical 3g TXA alone
Study: 26468213
Drug: Standard outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard outpatient treatment
Study: 11176086
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bupivacaine
Study: 30335610
Drug: Neutral Spinal
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral Spinal Spray (NSS)
Study: 22261004
Drug: Lidocaine (2mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (2mg/kg plus 50 μg/kg/min)
Study: 14503013
Drug: Other lipid
Normalized name: Other lipid modifying agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other lipid lowering agents
Study: 14503013
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-users of lipid-lowering agents)
Study: 10789718
Drug: Paclitaxel 80
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg m(‐2) over 3 h and nolatrexed 500 mg m(‐2) day(‐1) as a 120‐h continuous intravenous infusion (Schedule 1)
Study: 10789718
Drug: Paclitaxel 80
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg m(‐2) over 3 h and nolatrexed 500 mg m(‐2) day(‐1) as a 120‐h continuous intravenous infusion (Schedule 2)
Study: 10789718
Drug: Paclitaxel 80
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg m(‐2) over 3 h and nolatrexed 500 mg m(‐2) day(‐1) as a 120‐h continuous intravenous infusion (Schedule 3)
Study: 8969572
Drug: Verapamil COER‐24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil COER‐24 240 mg at 10 PM
Study: 1485477
Drug: Naftidrofuryl (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (400 mg for 7 days)
Study: 30558818
Drug: Quadrivalent inactivated
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent inactivated influenza vaccine (IIV4), two full doses 28 days apart.
Study: 24949544
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D supplementation (9 doses of 50,000 IU of cholecalciferol over 24 weeks)
Study: 22316314
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D supplementation
Study: 9866000
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (400 micrograms every 3 h for a maximum of five doses in 24 h)
Study: 9097753
Drug: Nimodipine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (oral administration, acute dose)
Study: 2771438
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural bupivacaine infusion
Study: 2771438
Drug: Intramuscular narcotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular narcotic analgesia
Study: 340134
Drug: Tinidazole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (single oral dose of 50 mg/kg)
Study: 340134
Drug: Metronidazole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (single oral dose of 50 mg/kg)
Study: 31144240
Drug: Probucol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (10 Âµmol/L) in hyperglycemia (30 mmol/L)
Study: 31144240
Drug: Hyperglycemia (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia (30 mmol/L)
Study: 21212932
Drug: Lowest tertile
Normalized name: textiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest tertile of serum potassium (2.8-3.9 mmol/l)
Study: 19302913
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation of topiramate 100 mg
Study: 11584936
Drug: Phlogenzym (2-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlogenzym (2-3 tablets, bid)
Study: 11584936
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 50 mg bid
Study: 9689205
Drug: Alora (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alora (0.05 mg/day applied for 3‐4 days)
Study: 9689205
Drug: Climara (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Climara (0.05 mg/day applied for 7 days)
Study: 29453445
Drug: Ketamine (NMDAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (NMDAR antagonist)
Study: 28711472
Drug: Nicotine (nAChR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (nAChR agonist)
Study: 26819186
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive treatment (VAAPS)
Study: 26819186
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Bascom cleft lift procedure)
Study: 22934446
Drug: Generic pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic pioglitazone (15 mg once daily)
Study: 20509069
Drug: Adjunctive VR
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive VR without hypnosis
Study: 18824708
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg sorafenib twice per day
Study: 18824708
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg sorafenib twice per day
Study: 15962376
Drug: 2‐wk regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐wk regimen consisting of ranitidine bismuth citrate 400 mg b.i.d. with clarithromycin 500 mg b.i.d.
Study: 8645625
Drug: Droloxifene 100
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 100 mg o.d. (group 2)
Study: 21183857
Drug: Intravenous mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous mannitol
Study: 1757907
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium taurocholate
Study: 6139318
Drug: Pindolol, 5
Normalized name: Pindolol, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol, 5 mg the evening before and on the morning, an hour prior to surgery
Study: 29645086
Drug: Erlotinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib plus placebo (erlotinib 150 mg daily)
Study: 12401597
Drug: 0.8 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mL/kg of 0.25% bupivacaine
Study: 12401597
Drug: 1.0 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mL/kg of 0.2% bupivacaine
Study: 2284217
Drug: Lornoxicam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (4 mg dose, administered as an aqueous solution, orally and intravenously)
Study: 26215551
Drug: Corticosteroid Injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid Injection (CSI)
Study: 20463410
Drug: saxagliptin (2.5‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin (2.5‐100 mg/d)
Study: 20463410
Drug: comparator (placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparator (placebo, metformin, uptitrated glyburide)
Study: 16143229
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR 37.5 mg/day
Study: 10199763
Drug: GnRHa plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa plus flutamide (250 mg, once daily)
Study: 530571
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment (all four corticosteroids)
Study: 29531101
Drug: Group-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based behavioral activation with mindfulness (BAM), provided with eight 2-hour weekly sessions.